Taken together with the parameters from ROC analysis on the serum Trx1 levels of various cancer patients summarized in Table 3, this data indicates that Trx1 can be used as a breast cancer marker capable of discriminating breast cancer patients from the female control at higher probability with superior sensitivity and specificity. This evidence concerns the gene TXN and breast carcinoma.